Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials

Clinical and Translational Medicine

Table 1 Currently approved checkpoint inhibitors

Drug name	Target	Manufacturer	Approved disease site
Ipilimumab	CTLA-4	Bristol-Meyers Squibb	Melanoma RCC^a
Pembrolizumab	PD-1	Merck	Melanoma NSCLC HNSCC HL PMBCL Urothelial carcinoma MSI-H/dMMR Solid Tumors Gastric Cancer Cervical Cancer
Nivolumab	PD-1	Bristol-Meyers Squibb	Melanoma RCC NSCLC HNSCC HL Urothelial carcinoma Colorectal cancer HCC
Avelumab	PD-L1	Merck/Pfizer	Merkel cell carcinoma RCC* Urothelial carcinoma
Durvalumab	PD-L1	Astra Zeneca	Urothelial carcinoma NSCLC
Atezolizumab	PD-L1	Genentech	Urothelial carcinoma NSCLC

RCC renal cell cancer, NSCLC non-small cell lung cancer, HNSCC head and neck squamous cell carcinoma, HL Hodgkin lymphoma (classic), PMBCL primary mediastinal B cell lymphoma, MSI-H microsatellite instability high, dMMR mismatch repair gene deficient, HCC hepatocellular carcinoma
^aApproval granted for use in combination with another therapeutic agent